Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ Quantitative Report
|
$69.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Regus plc SA Opens First Business Centre In Nepal
Regus plc announced that it has launched its first business centre in Nepal.
Latest Developments for Infinity Pharmaceuticals Inc
- Infinity Pharmaceuticals Inc Reports Phase 1 Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers
- Infinity Pharmaceuticals Inc Announces Updated Phase 1 Data Showing Encouraging Clinical Activity of IPI-145 in Chronic Lymphocytic Leukemia
- Infinity Pharmaceuticals Inc Announces Closing of Secondary Offering of Common Stock and Exercise of Over-Allotment Option
- Infinity Pharmaceuticals Inc Issues FY 2013 Earnings Guidance In Line With Analysts' Estimates
Latest Key Developments in Biotechnology
- La Jolla Pharmaceutical Co Announces FDA Acceptance Of IND For LJPC-501
- Portola Pharmaceuticals Inc Announces Positive Phase 2 Study Results Showing Factor Xa Inhibitor Antidote PRT4445 Reverses Anticoagulant Activity Of Eliquis
- Novavax Inc Announces Positive Top-Line Results From Phase 1 Clinical Trial Of RSV Vaccine Candidate In Elderly
- Norda ASA Announces Last Day of Trading
- Share this
- Link this
- Digg this
Follow Reuters